Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
28 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Protocol changes to the control arm of the pivotal Phase 3 trial for Iomab-B well received at the Company’s investigator meeting and by Iomab-B’s scientific advisory board - Product theater...
Actinium Pharmaceuticals Announces Commencement of Rights Offering Subscription Period
22 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Subscription period expected to end on March 2, 2018 at 5:00 PM ET NEW YORK, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"),...
Actinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
20 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
Actimab-MDS to be featured in a Product Theater on February 21st Members of Actinium’s executive and clinical development teams to participate in conference activities and extend the visibility of...
Actinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record
12 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
• To be a shareholder of record, investors are advised to own Actinium stock by 4:00 PM ET, Monday, February 12, 2018 to account for T+2 settlement timing • Actinium’s executive management and...
Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation
08 févr. 2018 08h00 HE
|
Actinium Pharmaceuticals
- Mr. Kapur joins Actinium with more than two decades of biopharmaceutical commercial experience at Johnson & Johnson, BAXALTA and Bristol-Myers Squibb - Global leader with deep expertise in...
Actinium Pharmaceuticals Reminds Investors of Record Date for Rights Offering
07 févr. 2018 09h00 HE
|
Actinium Pharmaceuticals
- Record date established as February 14, 2018 - To be a shareholder of record, investors are advised to own Actinium stock by 4:00 PM ET, Monday, February 12, 2018 to account for T+2 settlement...
Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients
06 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Actimab-A plus CLAG-M further expands Actinium’s CD33 program and addressable patient population of Actimab-A - Combination aligns with Actinium’s focus on improving bone marrow transplant access...
Actinium Pharmaceuticals to Present at the BIO CEO & Investor Conference
05 févr. 2018 16h15 HE
|
Actinium Pharmaceuticals
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it will be attending and presenting at the BIO CEO...
Actinium Pharmaceuticals Announces Rights Offering
01 févr. 2018 16h05 HE
|
Actinium Pharmaceuticals
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it has filed a preliminary prospectus supplement as...
Actinium Pharmaceuticals Provides Update on Pivotal Phase 3 Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial Continue
27 déc. 2017 09h00 HE
|
Actinium Pharmaceuticals
Actinium expects enhanced awareness of Iomab-B at ASH annual meeting and expanded site activity to enable completion of trial enrollment by end of 2018, in-line with prior forecast NEW YORK, Dec. ...